Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Semprus BioSciences, a biomedical company, has secured $8 million in series A financing co-led by 5AM Ventures and Pangaea Ventures. The proceeds of this financing will be used to advance Semprus's product candidates.
Subscribe to our email newsletter
Semprus is the developer of a new technology platform aimed at reducing medical device complications in areas of infections, thrombus, restenosis and bone integration. The company has previously raised $2.5 million in seed financing from private investors and 5AM Ventures.
David Lucchino, CEO of Semprus, said: “Patients suffer and the cost to hospitals and insurers is escalating due to a dramatic increase in infections and other preventable events. Our aim is to alleviate this pain by becoming the industry standard for reducing complications and healthcare costs associated with medical devices.
“Our investors continue to recognize the significant value that we are building by providing a solution for the delivery of high quality and efficient healthcare.”